The short version of Cardarine fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
It sought, and got, the king's acceptance to have an Irish minister, to the complete exclusion of British ministers, formally advise the king in the exercise of his powers and functions as king in the Free State. This gave the President of the Executive Council the right to directly advise the king in his capacity as His Majesty's Irish Prime Minister. Two examples of this are the signing of a treaty between the Free State and the Portuguese Republic in 1931, and the act recognising the abdication of King Edward VIII in 1936 separately from the recognition by the British Parliament. The unprecedented replacement of the use of the Great Seal of the Realm and its replacement by the Great Seal of Saorstát Éireann, which the king awarded to the Free State in 1931. (The Irish Seal consisted of a picture of King George V enthroned on one side, with the Irish state harp and the words Saorstát Éireann on the reverse. It is now on display in the Irish National Museum, Collins Barracks, Dublin.) When Éamon de Valera became President of the Executive Council (prime minister) in 1932 he described Cosgrave's ministers' achievements simply. Having read the files, he told his son, Vivion, "they were magnificent, son". The Statute of Westminster allowed de Valera, on becoming President of the Executive Council (February 1932), to go even further.
The "digital revolution" of the 21st century has brought newer technology to the art and science of tracheal intubation. Several manufacturers have developed video laryngoscopes which employ digital technology such as the CMOS active pixel sensor (APS) to generate a view of the glottis so that the trachea may be intubated. The Glidescope video laryngoscope is one example of such a device. Xenon, which does not act as a greenhouse gas, has recently been approved in some jurisdictions as an anaesthetic agent.
== Formation of short chain fatty acids == The oral administration of glucose elicits a much greater rise in blood insulin levels and a much lower rise in blood glucose levels than those elicited by intravenous glucose infusions. This difference, termed the incretin effect, is due to the activation of FFAR2-bearing intestinal cells by the short chain fatty acids (SCFAs) that intestinal bacteria excrete. The microbiotas inside the small intestine and colon of animals and humans consist of a wide range of microorganisms and viruses. The microorganisms ingest the food their hosts consume including soluble dietary fibers, e.g., resistant starch, xanthan gum, and inulin, all three of which are resistant to the hosts' digestive enzymes. Certain microorganisms (e.g., anaerobic bacteria), ferment these dietary fibers to form and then excrete SCFAs (primarily acetic, propionic, and butyric acids). The relative levels of these three SCFAs in the intestines of humans are about 60:20:20, respectively. Intestinal SCFAs activate FFAR2-bearing cells in the nearby intestinal walls and also enter the blood circulation to activate FFAR2-bearing cells in distant tissues. SCFAs may also be made and released by the bacteria and/or host cells in tissue that contain bacterial infections.
== Aim == Green nanotechnology has two goals: producing nanomaterials and products without harming the environment or human health, and producing nano-products that provide solutions to environmental problems. It uses existing principles of green chemistry and green engineering to make nanomaterials and nano-products without toxic ingredients, at low temperatures using less energy and renewable inputs wherever possible, and using lifecycle thinking in all design and engineering stages. In addition to making nanomaterials and products with less impact to the environment, green nanotechnology also means using nanotechnology to make current manufacturing processes for non-nano materials and products more environmentally friendly. For example, nanoscale membranes can help separate desired chemical reaction products from waste materials from plants. Nanoscale catalysts can make chemical reactions more efficient and less wasteful. Sensors at the nanoscale can form a part of process control systems, working with nano-enabled information systems. Using alternative energy systems, made possible by nanotechnology, is another way to "green" manufacturing processes. The second goal of green nanotechnology involves developing products that benefit the environment either directly or indirectly. Nanomaterials or products directly can clean hazardous waste sites, desalinate water, treat pollutants, or sense and monitor environmental pollutants.
Sources: en.wikipedia.org
Molybdenum(II) chloride MoCl2, which exists as the hexamer Mo6Cl12 and the related dianion [Mo6Cl14]2-. Molybdenum(III) chloride MoCl3, a dark red solid, which converts to the anion trianionic complex [MoCl6]3-. Molybdenum(IV) chloride MoCl4, a black solid, which adopts a polymeric structure. Molybdenum(V) chloride MoCl5 dark green solid, which adopts a dimeric structure. Molybdenum(VI) chloride MoCl6 is a black solid, which is monomeric and slowly decomposes to MoCl5 and Cl2 at room temperature. The accessibility of these oxidation states depends quite strongly on the halide counterion: although molybdenum(VI) fluoride is stable, molybdenum does not form a stable hexachloride, pentabromide, or tetraiodide. Like chromium and some other transition metals, molybdenum forms quadruple bonds, such as in Mo2(CH3COO)4 and [Mo2Cl8]4−. The Lewis acid properties of the butyrate and perfluorobutyrate dimers, Mo2(O2CR)4 and Rh2(O2CR) 4, have been reported. The oxidation state 0 and lower are possible with carbon monoxide as ligand, such as in molybdenum hexacarbonyl, Mo(CO)6.
== Plot summary == The protagonist is Bob Arctor, member of a household of drug users, who is also living a double life as an undercover police agent assigned to spy on Arctor's household. There are several humorous and darkly humorous episodes involving Arctor and his roommates. Arctor shields his identity from those in the drug subculture and from the police. (The requirement that narcotics agents remain anonymous, to avoid collusion and other forms of corruption, becomes a critical plot point late in the book.) While posing as a drug user, Arctor becomes addicted to "Substance D", a powerful psychoactive drug. A conflict is Arctor's love for Donna, a drug dealer, through whom he intends to identify high-level dealers of Substance D. Substance D, also called "Slow Death" or simply "D" is a drug of unknown origin, manufacture and distribution. When performing his work as an undercover agent, Arctor goes by the name "Fred" and wears a "scramble suit" that conceals his identity from other officers. Then he is able to sit in a police facility and observe his housemates through "holo-scanners", audio-visual surveillance devices that are placed throughout the house. Arctor's use of the drug causes the two hemispheres of his brain to function independently or "compete". When Arctor sees himself in the videos saved by the scanners, he does not realize that it is him. Through a series of drug and psychological tests, Arctor's superiors at work discover that his addiction has made him incapable of performing his job as a narcotics agent.
=== Chronic wounds === A 2015 review found that the evidence supporting the use of electrotherapy in healing pressure ulcers was of low quality, and a 2015 Cochrane review found no evidence that electromagnetic therapy, a subset of electrotherapy, was effective in healing pressure ulcers. Earlier reviews found that, because of low-quality evidence, it was unclear whether electrotherapy increases healing rates of pressure ulcers. By 2014 the evidence supported electrotherapy's efficacy for ulcer healing. Another 2015 Cochrane review found no evidence supporting the use of electrotherapy for venous stasis ulcers.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.